Sign in

You're signed outSign in or to get full access.

Anna Skowron

Chief Financial Officer at ENTO
Executive

About Anna Skowron

Anna Skowron (age 38) was appointed Interim Chief Financial Officer of Entero Therapeutics on March 7, 2025. She is a licensed CPA (Ontario) and principal of Skowron Accounting Professional Corporation since 2015, with 14+ years of experience spanning financial reporting, compliance, corporate governance, business strategy, consolidated reporting across North America for a global steel corporation, and Global Financial Controller experience at a multi-national technology provider. She holds a Bachelor of Commerce and Finance (Accounting and Economics) from the University of Toronto and became a member of the Institute of Chartered Accountants of Ontario in 2014 . Her appointment is under a CFO consulting agreement paying $8,333 per month effective March 7, 2025, renewable month-to-month with 10 business days’ termination notice, and standard indemnification; no equity awards were disclosed at appointment .

Company performance context (pre-tenure):

MetricFY 2022FY 2023FY 2024
Value of Initial $100 Investment (TSR)$(48.49) $(28.20) $(0.10)
Net Loss ($)$(14,629,642) $(15,794,983) $(18,059,336)

Past Roles

OrganizationRoleYearsStrategic Impact
Skowron Accounting Professional CorporationPrincipal2015–present Provided CFO-level services, financial reporting, compliance, governance, and business strategy; key role in acquisitions and capital raising across industries
Global steel corporation (North America)Consolidated Reporting ManagerManaged consolidated reporting across North America
Multi-national North American-domiciled technology providerGlobal Financial ControllerLed global financial control for technology operations

External Roles

No public company directorships or committee roles were disclosed in the 2025 DEF 14A and March 2025 8-K appointing Skowron .

Fixed Compensation

ComponentAmountEffective DateTerms
CFO consulting fee (monthly)$8,333.33 March 7, 2025 Month-to-month renewal; either party may terminate with 10 business days’ notice; pro-rata payment upon termination
Expense reimbursementAs incurred, per policyOngoingReasonable business expenses reimbursed within policy timelines with substantiation
Indemnification & D&OPolicy maintainedOngoingFull indemnification to fullest extent permitted under DGCL; D&O liability coverage maintained

Notes:

  • The agreement is an independent contractor arrangement; no employee benefits (vacation, retirement, health, etc.) and tax obligations borne by consultant .
  • Choice of law: New York; arbitration under AAA; submission to New York courts; survives termination in specified respects .

Performance Compensation

No target bonus %, actual bonus, RSUs/PSUs, options, or performance metric weightings were disclosed for Skowron at or since appointment. The CFO consulting agreement specifies cash-only monthly compensation without variable pay components or equity grants .

Equity Ownership & Alignment

CategoryDetail
Beneficial ownership (as of May 15, 2025)“—” shares; percent “—” (company-wide base 4,765,729 shares outstanding)
Vested vs. unvested sharesNot disclosed for Skowron
Options (exercisable/unexercisable)Not disclosed for Skowron
Shares pledged as collateralNo pledging disclosure for Skowron; company policy prohibits short selling and hedging; all insider transactions must be pre-cleared by the CFO
Ownership guidelinesNo executive stock ownership multiple-of-salary guideline disclosed; insider trading policy mandates pre-clearance and blackout compliance; Rule 10b5-1 plan guidelines included

Policy alignment signals:

  • Hedging and short selling are prohibited for all insiders; transactions require pre-clearance by the CFO, and blackout periods apply .
  • Indemnification agreement includes exceptions for compensation recovery and Section 16(b), indicating exposure to clawback/recovery under applicable laws even if formal company clawback policy is not described in the proxy .

Employment Terms

TermDetail
Engagement structureNon-employee CFO via Skowron Accounting Professional Corporation
Start dateEffective March 7, 2025
Compensation$8,333.33 per month; subject to periodic review
Term & renewalMonth-to-month; terminable by company or consultant with 10 business days’ notice
Confidentiality & IPStrict confidentiality; company property retained by company; survives termination
ConflictsProhibits engaging in activities causing a conflict of interest; company may terminate upon material conflict
Indemnification & D&OFull indemnification to fullest extent under DGCL; D&O insurance maintained, coverage customary
Dispute resolutionNew York law; AAA arbitration; New York jurisdiction

Governance & Shareholder Feedback (context)

Item2025 Vote Outcome
Say-on-Pay (advisory)For 415,176; Against 77,434; Abstain 15,048; Broker non-votes 1,328,218
Board electionFive directors elected for one-year term
Reverse split authorizationApproved (ratio 1:2 to 1:20)

Investment Implications

  • Alignment: Cash-only, month-to-month consulting arrangement with no disclosed equity grants or ownership suggests limited direct equity alignment. Beneficial ownership shows no shares for Skowron as of May 15, 2025, reducing near-term insider selling pressure but also limiting alignment with TSR goals .
  • Retention risk: The CFO agreement’s at-will, month-to-month structure with 10 business days’ termination notice elevates transition risk versus typical multi-year executive employment agreements with severance/change-of-control protections .
  • Control & compliance: CFO-centric pre-clearance and blackout enforcement strengthens trading controls; hedging/short selling prohibitions are a positive governance signal, though pre-clearance by the CFO requires robust oversight to mitigate self-clear risks .
  • Pay-for-performance: No disclosed variable pay or performance metrics tied to Skowron’s compensation; if continued, this structure may emphasize near-term cash discipline over incentive-driven strategic outcomes relative to TSR and profitability targets .
  • Monitoring signals: Watch for future Form 4 filings indicating any equity acquisitions by Skowron, adoption of Rule 10b5-1 plans, or subsequent equity grants via proxy/8-K as potential shifts in alignment. Also monitor any updates to clawback policy disclosures and insider trading policy administration in future proxies/8-Ks .